# US 2024/0383899 A1 · Modified carbapenem antibiotics with improved activity against kpc carbapenemase-producing enterobacterales

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0383899 A1
- Document ID: US20240383899A1
- Status: Published application
- Kind: A1
- Application number: 18/659,427
- Filed: 2024-05-09
- Published: 2024-11-21
- Earliest claimed: 2023-05-15
- Assignees: Southern Methodist University
- Applicants: Southern Methodist University
- Inventors: John D. Buynak; Taariq Hassan; Pojun Quan
- Web page: https://patentgrep.com/patent/US20240383899A1

## CPC

- C07D 477/20: Sulfur atoms
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are the design, preparation, evaluation, and use of structurally modified carbapenem antibiotics with improved activity, relative to current commercially available carbapenem antibiotics, against infections involving multidrug-resistant, carbapenemase-producing Enterobacterales strains. In particular, the new carbapenem antibiotics are demonstrated to produce improved activity, relative to current commercial carbapenem antibiotics, against bacterial strains producing a KPC carbapenemase. This invention includes their use as standalone antibiotics, as well as synergistic mixtures of the structurally modified carbapenems with carbapenemase inhibitors as well as synergistic mixtures of the newly modified carbapenems with other carbapenem antibiotics.

## Claims

### Claim 1

A compound of Formula I, or a pharmaceutically acceptable salt or ester thereof:
R1=H or CH3;
n=0 or 1;
R2 is H, CH2NHSO2NH2, or CONRaRb, where Ra and Rb may be independently equal to H, Me, Aryl, or substituted Aryl; and
R3 is H, dihydrothiazole, C1 to C6 Alkyl, or R3=CORc, where Rc=C1 to 6 alkyl, aryl, substituted aryl, or Rc=NHRd, where Rd=H, aryl or substituted aryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 3 (depends on 1)

The compound of claim 1, wherein the —CO2M, which is attached to the carbapenem nucleus at position 3, wherein M is a carboxylic acid group (M represents H), a carboxylate anion (M represents a negative charge), a pharmaceutically acceptable ester (M represents an ester forming group) or a carboxylic acid protected by a protecting group (M represents a carboxyl protecting group).

### Claim 4 (depends on 1)

The compound of claim 1, wherein the pharmaceutically acceptable salts form —COOM, where M is a negative charge, which is balanced by a counterion, an alkali metal cation, sodium, potassium calcium, magnesium, zinc, ammonium, or alkylammonium cations such as tetramethylammonium, tetrabutylammonium, choline, triethylhydroammonium, meglumine, or triethanolhydroammonium; or the pharmaceutically acceptable salts comprise acid addition salts, inorganic, or organic acids.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the pharmaceutically acceptable salts comprise acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, or undecanoate.

### Claim 6 (depends on 1)

The compound of claim 1, wherein at least one of:
the pharmaceutically acceptable ester is a hydrolyzable ester;
the hydrolyzable esters is biologically hydrolyzable, is suitable for oral administration, has good absorption through the stomach or intestinal mucosa, or resistance to gastric acid degradation; or
the hydrolyzable ester M is selected from at least one of: an alkoxyalkyl, alkylcarbonyloxyalkyl, alkoxycarbonyloxyalkyl, cycloalkoxyalkyl, alkenyloxyalkyl, aryloxyalkyl, alkoxyaryl, alkylthioalkyl, cycloalkylthioalkyl, alkenylthioalkyl, arylthioalkyl or alkylthioaryl group. These groups can be substituted in the alkyl or aryl portions thereof with acyl or halo groups. The following M species are examples of biolabile ester forming moieties: acetoxymethyl, 1-acetoxyethyl, 1-acetoxypropyl, pivaloyloxymethyl, 1-isopropyloxycarbonyloxyethyl, 1-cyclohexyloxycarbonyloxyethyl, phthalidyl and (2-oxo-5-methyl-1,3-dioxolen-4-yl)methyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is selected from at least one of:

### Claim 8

A method of making the compound of Formula I, comprising:

### Claim 9

A composition comprising:
a compound of Formula I, or a pharmaceutically acceptable salt or ester thereof:
R1=H or CH3;
n=0 or 1;
R2 is H, CH2NHSO2NH2, or CONRaRb, where Ra and Rb may be independently equal to H, Me, Aryl, or substituted Aryl; and
R3 is H, dihydrothiazole, C1 to C6 Alkyl, or R3=CORc, where Rc=C1 to 6 alkyl, aryl, substituted aryl, or Rc=NHRd, where Rd=H, aryl or substituted aryl; and
a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the compound is:

### Claim 11 (depends on 9)

The composition of claim 9, wherein the —CO2M, which is attached to the carbapenem nucleus at position 3, wherein M is a carboxylic acid group (M represents H), a carboxylate anion (M represents a negative charge), a pharmaceutically acceptable ester (M represents an ester forming group) or a carboxylic acid protected by a protecting group (M represents a carboxyl protecting group).

### Claim 12 (depends on 9)

The composition of claim 9, wherein the pharmaceutically acceptable salts form-COOM, where M is a negative charge, which is balanced by a counterion, an alkali metal cation, sodium, potassium calcium, magnesium, zinc, ammonium, or alkylammonium cations such as tetramethylammonium, tetrabutylammonium, choline, triethylhydroammonium, meglumine, or triethanolhydroammonium; or the pharmaceutically acceptable salts comprise acid addition salts, inorganic, or organic acids.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the pharmaceutically acceptable salts comprise acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, or undecanoate.

### Claim 14 (depends on 9)

The composition of claim 9, wherein at least one of:
the pharmaceutically acceptable ester is a hydrolyzable ester;
the hydrolyzable esters is biologically hydrolyzable, is suitable for oral administration, has good absorption through the stomach or intestinal mucosa, or resistance to gastric acid degradation; or
the hydrolyzable esters M is selected from at least one of: an alkoxyalkyl, alkylcarbonyloxyalkyl, alkoxycarbonyloxyalkyl, cycloalkoxyalkyl, alkenyloxyalkyl, aryloxyalkyl, alkoxyaryl, alkylthioalkyl, cycloalkylthioalkyl, alkenylthioalkyl, arylthioalkyl or alkylthioaryI group. These groups can be substituted in the alkyl or aryl portions thereof with acyl or halo groups. The following M species are examples of biolabile ester forming moieties: acetoxymethyl, 1-acetoxyethyl, 1-acetoxypropyl, pivaloyloxymethyl, 1-isopropyloxycarbonyloxyethyl, 1-cyclohexyloxycarbonyloxyethyl, phthalidyl and (2-oxo-5-methyl-1,3-dioxolen-4-yl)methyl.

### Claim 15 (depends on 9)

The composition of claim 9, wherein the compound is at least one of:

### Claim 16 (depends on 9)

The composition of claim 9, further comprising an amount of a structurally modified carbapenem with carbapenemase inhibitors and synergistic mixtures of the compound of Formula I with other carbapenem antibiotics.

### Claim 17

A method of treating a bacterial infection comprising:
contacting a bacteria with a compound of Formula I, or a pharmaceutically acceptable salt or ester thereof:
R1=H or CH3;
n=0 or 1;
R2 is H, CH2NHSO2NH2, or CONRaRb, where Ra and Rb may be independently equal to H, Me, Aryl, or substituted Aryl; and
R3 is H, dihydrothiazole, C1 to C6 Alkyl, or R3=CORc, where Rc=C1 to 6 alkyl, aryl, substituted aryl, or Rc=NHRd, where Rd=H, aryl or substituted aryl; and
a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound is:

### Claim 19 (depends on 17)

The method of claim 17, wherein the —CO2M, which is attached to the carbapenem nucleus at position 3, wherein M is a carboxylic acid group (M represents H), a carboxylate anion (M represents a negative charge), a pharmaceutically acceptable ester (M represents an ester forming group) or a carboxylic acid protected by a protecting group (M represents a carboxyl protecting group).

### Claim 20 (depends on 17)

The composition of claim 17, wherein the pharmaceutically acceptable salts form —COOM, where M is a negative charge, which is balanced by a counterion, an alkali metal cation, sodium, potassium calcium, magnesium, zinc, ammonium, or alkylammonium cations such as tetramethylammonium, tetrabutylammonium, choline, triethylhydroammonium, meglumine, or triethanolhydroammonium; or the pharmaceutically acceptable salts comprise acid addition salts, inorganic, or organic acids.

### Claim 21 (depends on 17)

The method of claim 17, wherein the pharmaceutically acceptable salts comprise acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, or undecanoate.

### Claim 22 (depends on 17)

The method of claim 17, wherein at least one of:
the pharmaceutically acceptable ester is a hydrolyzable ester;
the hydrolyzable esters is biologically hydrolyzable, is suitable for oral administration, has good absorption through the stomach or intestinal mucosa, or resistance to gastric acid degradation; or
the hydrolyzable esters M is selected from at least one of: an alkoxyalkyl, alkylcarbonyloxyalkyl, alkoxycarbonyloxyalkyl, cycloalkoxyalkyl, alkenyloxyalkyl, aryloxyalkyl, alkoxyaryl, alkylthioalkyl, cycloalkylthioalkyl, alkenylthioalkyl, arylthioalkyl or alkylthioaryl group. These groups can be substituted in the alkyl or aryl portions thereof with acyl or halo groups. The following M species are examples of biolabile ester forming moieties: acetoxymethyl, 1-acetoxyethyl, 1-acetoxypropyl, pivaloyloxymethyl, 1-isopropyloxycarbonyloxyethyl, 1-cyclohexyloxycarbonyloxyethyl, phthalidyl and (2-oxo-5-methyl-1,3-dioxolen-4-yl)methyl.

### Claim 23 (depends on 17)

The method of claim 17, wherein the compound is at least one of:

### Claim 24 (depends on 17)

The method of claim 17, further comprising an amount of a structurally modified carbapenem with carbapenemase inhibitors and synergistic mixtures of the compound of Formula I with other carbapenem antibiotics.
